Up a level |
Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J ORCID: 0000-0001-5608-001X, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L et al (show 38 more authors)
(2022)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
LANCET, 399 (10323).
pp. 447-460.
James, Nicholas D, Clarke, Noel W, Cook, Adrian, Ali, Adnan, Hoyle, Alex P, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William R, Dearnaley, David P et al (show 46 more authors)
(2022)
Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).
INTERNATIONAL JOURNAL OF CANCER, 151 (3).
pp. 422-434.
Clarke, Caroline S, Hunter, Rachael M, Gabrio, Andrea, Brawley, Christopher D, Ingleby, Fiona C, Dearnaley, David P, Matheson, David, Attard, Gerhardt, Rush, Hannah L, Jones, Rob J ORCID: 0000-0001-5608-001X et al (show 12 more authors)
(2022)
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
PloS one, 17 (6).
e0269192-e0269192.
Hussain, Syed A, Palmeri, Daniel H, Syn, Wing-Kin, Sacco, Joseph J, Greensmith, Richard MD, Elmetwali, Taha, Aachi, Vijay, Lloyd, Bryony H, Jithesh, Puthen V, Arrand, John et al (show 4 more authors)
(2017)
Gene expression profiling in bladder cancer identifies potential therapeutic targets.
INTERNATIONAL JOURNAL OF ONCOLOGY, 50 (4).
pp. 1147-1159.